Immediate injection pain in infants aged 18 months during vaccination against measles, mumps and rubella with either Priorix super([registered]) or MMR- II super([registered])

The aim of this study was to investigate whether, the vaccine Priorix super([registered]) causes less immediate injection pain than MMR- II super([registered]) in vaccination of infants aged 18-24 months who were offered vaccine against measles, mumps and rubella. The infants were randomised into on...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2006-07, Vol.24 (31-32), p.5800-5805
Main Authors: Knutsson, Nina, Jansson, Ulla-Britt, Alm, Bernt
Format: Article
Language:English
Subjects:
Measles virus
Mumps virus
Rubella virus
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to investigate whether, the vaccine Priorix super([registered]) causes less immediate injection pain than MMR- II super([registered]) in vaccination of infants aged 18-24 months who were offered vaccine against measles, mumps and rubella. The infants were randomised into one of the two vaccine groups (Priorix super([registered])/MMR-II super([registered])) in a double-blind study. One observer assessed pain, using CHEOPS (Children's Hospital Eastern Ontario Pain scale), and the parent used the Visual Analogue Pain scale (VAS). Pain assessment was made in 295 infants. Mean age was 19.08 months. Mean VAS value was 2.3/5.2 for Priorix super([registered]) and MMR- II super([registered]), respectively (p - 0.001). Mean CHEOPS value was 1.9/6.1 for Priorix super([registered]) and MMR-II super([registered]), respectively (p - 0.001). The study shows that Priorix super([registered]) gives less immediate injection pain than MMR-II super([registered]).
ISSN:0264-410X
DOI:10.1016/j.vaccine.2006.05.004